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Abstract
The ovarian cancer microenvironment recruits an array of immune cells to the site of tumor growth. Within the
peritoneal ascites of both humans and mice, the predominant population of tumor-infiltrating leukocytes is a
CD11c+CD11b+ population variably referred to as vascular leukocytes (VLCs), tumor-associated macrophages, and
immature dendritic cells. We have previously shown that these cells are critical for tumor growth because their
selective elimination from the peritoneal tumor microenvironment inhibited tumor progression. However, the under-
lying mechanism by which this therapy was efficacious is poorly understood. Here, we use the murine ID8 ovarian
tumormodel to demonstrate that the tumor microenvironment induces in vivo immunosuppression of T cells and that
the SR-A+ VLCs mediate this suppression. Importantly, the elimination of SR-A+ VLCs from the peritoneum of tumor-
bearing mice relieves the T cell suppression. Moreover, the profound changes that VLC elimination has on the
immune system are T cell–dependent because the protective antitumor effect of VLC elimination does not occur
when CD8 T cells are concomitantly depleted. These results were confirmed and extended with the use of a genetic
model for VLC depletion, which demonstrated that short-term therapeutic depletion of VLCs alleviates immuno-
suppression and allows for efficacious vaccination against model tumor antigens in tumor-bearing mice. These
studies provide a mechanistic explanation for how leukocytes contribute to ovarian tumor progression and, corre-
spondingly, how leukocyte depletion inhibits tumor growth.
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Introduction
Tumor growth in a variety of tissues is associated with an influx of
immune cells including T regulatory cells, tumor-associated macro-
phages, inhibitory dendritic cells, and myeloid-derived suppressor cells
(MDSCs). These cells are co-opted by the tumor to sculpt the local
tumor environment into an area permissive for tumor growth and
metastasis through immunosuppression, angiogenesis, and tissue re-
modeling [1–6]. Indeed, leukocyte accumulation in tumor tissue is
correlated with poor clinical outcome [7,8].
Specifically, both human and murine ovarian carcinomas and their
associated ascites are infiltrated with a variety of immune cells [9–12].
The ID8 mouse model of ovarian cancer [13] faithfully reproduces the
clinical progression in this regard in that it produces a robust peritoneal
ascites into which it recruits an influx of CD11c+CD11b+SR-A+ leuko-
cytes, which have been referred to as tumor-associated macrophages,
immature DCs, and vascular leukocytes (VLCs) [14–16]. Importantly,
these peritoneal VLCs are critical to tumor progression: by exploiting
the expression of scavenger receptor-A (SR-A) on VLCs, we previously
demonstrated that the targeted elimination of VLCs from the perito-
neum of ID8-challenged mice led to a reduction in ascites volume and
tumor burden [14]. Subsequent in vitro studies demonstrated that
VLCs isolated from the tumor ascites function as MDSCs, inhibit-
ing CD8 and CD4 T cell responses through an arginase-1 (ARG1)–
dependent mechanism [17].
The induction of MDSCs at the site of primary tumor growth is
associated with the presence of suppressive CD11b+Gr-1+ MDSCs
in secondary lymphoid tissues and suppression of global immune
responses [18]. Because ID8-induced VLCs constitute an immuno-
suppressive cell population, we hypothesized that ID8 tumor growth
will lead to dysregulation of immune responses distal to tumor growth
and that this suppression potentiates tumor growth. However, it is
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currently unknown whether VLCs abet tumor progression through their
function as MDSCs nor is it known whether in vivo removal of these
immunosuppressive cells from the ovarian tumor microenvironment
can relieve the immunosuppression.
In this study, we demonstrate that the ID8 ovarian tumor induces
both local and systemic in vivo T cell immunosuppression. Importantly,
we show that VLCs are required to mediate this effect, and more-
over, VLC depletion reverses the immunosuppressive tumor micro-
environment and alleviates the T cell immunosuppression. Indeed,
even short-term therapeutic VLC depletion relieves immunosuppression
and allows for the induction of a peptide-specific immune response.
Consistent with previous studies [14,15], we demonstrate that VLC
depletion is sufficient to impair peritoneal ID8 tumor progression. Here,
we tie together the role of VLCs as immunosuppressive cells and their
function as obligate tumor-promoting cells by defining their in vivo effect
on the immune system. We demonstrate that the suppressive effect of
tumor growth on the host immune system is reversed through VLC de-
pletion. Relevant to their role as immunosuppressive cells, we show that
the reduced tumor growth mediated by VLC depletion is partially de-
pendent on CD8+ T cells. These results will be discussed in the context
of tumor-induced immune dysfunction and the implications on cur-
rent immunotherapies against cancer.
Materials and Methods
Mice and Antibodies
Female C57Bl/6 and CB6/F1 mice (4-6 weeks old) were purchased
from the National Cancer Institute (Fredericksburg, MD). C57Bl/6-
RAG−/− and Balb/c-RAG−/− were purchased from Jackson Laboratories
(Bar Harbor, ME) and CB6/F1 RAG−/− mice were used in indicated
experiments. MAFIA mice [19] were purchased from Jackson Labora-
tories under agreement with Ariad Pharmaceuticals (Cambridge, MA).
Animal experiments were approved by the Dartmouth Medical School
Institutional Animal Care and Use Committee. Antimouse Fc-Block
and antimouse CD11c (HC3) were purchased from BD Biosciences
(San Jose, CA). Antimouse CD3 antibody (145-2C11), CD11b (M1/
70), andGr-1 (RB6-8C5)were purchased from eBiosciences (SanDiego,
CA). Antimouse CD8 antibody (53-6.7) was purchased from Biolegend
(San Diego, CA).
Generation of Tumors and Harvest of
Tumor-Associated Leukocytes
Ovarian tumors were generated and harvested as previously de-
scribed [14]. Briefly, mice were injected intraperitoneally (i.p.) with
5 × 106 ID8 cells. Approximately 6 weeks later, peritoneal ascites
were harvested. The cellular fraction was treated with ACK lysis buffer
(0.15 M NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA) to remove red
blood cells, and the remaining cells were resuspended in 0.5% BSA in
PBS or medium for analysis. In indicated experiments, single-cell sus-
pensions of spleens were generated from naive or tumor-challenged
mice by digestion with collagenase/DNAse and passage through a
70-μM cell strainer (BD Biosciences).
Flow Cytometry
Cells from murine ascites were resuspended at 1 × 106 cells/ml in
0.5% BSA in PBS with Fc-blocking antibody and subsequently
stained with the indicated antibodies. Flow cytometry was performed
at the NCCC Englert Cell Analysis Laboratory using a FACS Calibur
or FACS Aria (BD Biosciences) and analyzed with FloJo 8.8.4 Software
(FloJo, Ashland, OR).
Splenocyte Activation Assays
Splenocytes were derived from mice as described previously. A total
of 106 splenocytes were resuspended in medium and, as indicated,
stimulated with 1 μg of plate-bound αCD3 antibody or a combination
of 50 nM phorbol 12-myristate acetate (PMA) and 0.5 μM ionomycin
(Sigma, St Louis, MO) and incubated at 37°C. After 72 hours, the cells
were spun down, and supernatants were removed for ELISA. Super-
natants were assayed for interferon-γ (IFN-γ) content using the murine
DuoSet ELISA (R&D Systems, Minneapolis, MN) according to the
manufacturer’s protocol. In indicated experiments, CD11b+ cells from
tumor-bearing or naive mice were isolated from splenocyte preparations
through positive selection using Miltenyi CD11b magnetic beads
(Miltenyi Biotec, Auburn, CA).Where indicated, 105 CD11b+ cells were
added to naive splenocytes as previously mentioned.
Anti–SR-A Depletion of VLCs and CD8 Depletion
Preparation of anti–SR-A immunotoxin: 4.8 μg of Rat-ZAP in the
absence (ZAP) or presence of 4 μg of clone 2F8 rat antimouse SR-A
antibody (SRA-ZAP) was incubated on ice for 30 minutes. CB6/F1
mice were injected i.p. with 5 × 106 ID8-C3 cells, in conjunction with
SRA-ZAP or ZAP, on day 0. Additional administrations of SRA-ZAP
or ZAP were then given every 7 days. Indicated mice were injected with
250 μl of anti-CD8 antibody, 2.43 mAb, a generous gift of Dr. Mary
Jo Turk (Dartmouth Medical School, Lebanon, NH). Mice were
weighed weekly to monitor tumor progression and were killed when
an increase in body weight of 75% was observed. In indicated experi-
ments, all mice were killed after 7 weeks, ascites volume was measured,
and ascites cellularity was assessed after ACK lysis of RBC; in some cases,
peritoneal lavage was necessary for mice with ascites less than 5 ml.
Cells were stained with anti-CD11c antibody, and numbers of
CD11c+ (CD11c+GFP−) and tumor cells (CD11c−GFP+) in the peri-
toneum of the mice were calculated by flow cytometry. Data are derived
from three separate experiments, with a total of at least six mice in each
treatment group.
Serum ELISAs
Ascites was collected from the peritoneum of tumor-bearing mice
under the indicated treatment regimen, and samples were centrifuged
for 10 minutes at 15,000g. Serum was collected and centrifuged once
more for 10 minutes at 15,000g to remove any additional debris.
Interleukin 10 (IL-10) and IFN-γ content was assessed by ELISA
using the murine DuoSet ELISA (R&D Systems) according to the
manufacturer’s protocol.
AP20187 Treatment
AP20187 was obtained under agreement with Ariad Pharmaceuti-
cals. MAFIA mice were treated with AP20187 as previously described
[19,20]. Briefly, mice were treated with 10 μg of AP20187 per
mouse in 450 μl of injection solution consisting of 4% ethanol, 10%
PEG-400, and 1.7% Tween-20 in water. Control mice were treated
with 450 μl of injection solution alone. To test the efficacy of
AP20187 depletion of VLCs, MAFIA mice were injected with 1 ×
106 ID8 cells; 6 weeks later, mice were treated with AP20187 or injec-
tion solution for three straight days. Mice were killed, and the post-
RBC lysis fraction of ascites was stained with anti-CD11c antibody
and assessed by flow cytometry.
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Immunization and VLC Depletion
MAFIA mice were injected with 1 × 106 ID8 cells. At 5 to 6 weeks
after tumor injection, mice were treated with AP20187 or injec-
tion solution, every other day for 5 days, for a total of three injections.
On day 5, indicated mice were injected retro-orbitally with 2 μg of
SIINFEKL peptide/10 μg of lipopolysaccharide/100 μg of agonistic
αCD40 antibody (gift of the Noelle Laboratory, Dartmouth Medical
School). After 72 hours, splenocytes were harvested as previously men-
tioned and were incubated with 1 μg/ml SIINFEKL peptide, or 50 nM
PMA and 0.5 μM ionomycin, and 10 μg/ml brefeldin A in complete
medium at 37°C for 5 hours. Cells were stained with anti-CD8, fixed,
and rendered permeable before staining with anti–IFN-γ. Percentages
of CD8+ and IFN-γ+ cells were determined in comparison to non–
tumor-treated, vehicle-injected, MAFIA mice.
Results
Peritoneal ID8 Tumors Suppress Distal T Cell Activity
through VLCs
It is well established that CD11b+Gr-1+ cells harvested from tumor-
bearing mice can suppress T cell responses [18,21,22]. Consistent with
this, we previously reported that CD11c+CD11b+ VLCs derived from
ID8 peritoneal ascites can function as MDSCs to inhibit CD8+ and
CD4+ T cell responses in vitro [17]. However, during ID8 tumor pro-
gression, CD11b+Gr-1+ cells are also present in anatomy distal to the
immediate tumor microenvironment, including the spleens of tumor-
bearing mice. To test whether the presence of these cell populations
influences T cell activity in lymphoid tissues distal to the tumor, we
assayed splenic T cells from tumor-bearing and control naive mice. On
activation either with an anti-CD3 antibody or with PMA/ionomycin,
splenic CD8+ T cells from mice with 6-week ID8 peritoneal tumors
produced substantially less IFN-γ in comparison to naive controls
(Figure 1A). Because CD11b+ cells from spleens of tumor-bearing
mice in a variety of tumor models are immunosuppressive, we tested
whether CD11b+ cells from ID8 tumor-bearing mice are suppressive.
We harvested CD11b+ cells from the spleens of naive and tumor-bearing
mice and added them to stimulated naive splenocytes. CD11b+ cells
from tumor-bearing mice suppress naive T cells in comparison to their
naive counterparts, as assessed by IFN-γ production (Figure 1B). These
results demonstrate that ID8 tumor growth causes suppression of the
immune system in distal lymphoid tissues and the induction of a sup-
pressive phenotype in the splenic CD11b+ compartment.
VLC Depletion Inhibits Tumor-Induced Immunosuppression
Because VLCs are immunosuppressive cells [14], we wanted to as-
certain whether they are necessary for the in vivo immunosuppression
seen in Figure 1. To test this, we used an SR-A immunotoxin that, as
we previously demonstrated, removed tumor-promoting leukocytes
within the peritoneum of ID8-challenged mice and thereby slowed
ID8 tumor progression and reduced tumor burden [14]. To test whether
Figure 1. ID8 tumor growth suppresses splenic responses. (A) A total of 1 × 106 splenocytes from naive mice (black bars) andmice bearing
6-week ID8 ovarian tumors (white bars) were stimulated with media alone (negative), αCD3 antibody (αCD3), or PMA and ionomycin (PMA)
for 72 hours. Culture supernatants were harvested, and IFN-γ was assessed by ELISA. (B) A total of 1 × 106 splenocytes from naive mice
were left unstimulated (negative) or stimulated with αCD3 antibody (αCD3), in the presence of media alone (black bars), 105 CD11b+ spleno-
cytes from tumor-bearing mice (white bars), or 105 CD11b+ splenocytes from naive mice (hashed bars), and IFN-γ was assessed in the
cell supernatant by ELISA 72 hours later. Statistical significance (*P < .05; **P < .01) was determined with the paired Student’s t test.
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VLCs are not only sufficient but also necessary for tumor-induced
immunosuppression (Figure 1), we tested whether SR-A–mediated
VLCdepletion restoredT cell activity in lymphoid tissues of treatedmice.
CD3- and PMA-stimulated T cells from mice treated with control toxin
were unable to produce substantial IFN-γ after 7 weeks of tumor growth
(Figure 2A). However, when mice were treated weekly with the SR-A
immunotoxin, splenic T cells were then able to be activated ex vivo as
assessed by IFN-γ production (Figure 2A). This occurred independently
of an observable change in the splenic MDSC population (Figure 2B).
Consistent with previous results, SR-A depletion effectively reduces the
number of CD11c+ cells from the peritoneum of tumor-bearing mice
[14] but has no effect on the splenic MDSC population (Figure 2C).
These results demonstrate that removal of SR-A+ cells from the perito-
neum affects distal lymphoid tissues with no demonstrable change
in the number of CD11b+ cells in the spleen. Therefore, we tested the
effect of SR-A+ cell depletion on the local cytokine milieu at the site of
tumor growth.
VLC Depletion Modifies the Peritoneal Cytokine Milieu
SR-A depletion relieves splenic immunosuppression in ID8-bearing
mice, and T cell activity was restored despite similar splenic MDSC
populations in SR-A– and control-treated mice. Therefore, we
assessed whether depletion of SR-A+ cells in the peritoneum of
tumor-bearing mice altered the immunosuppressive cytokine envi-
ronment. We analyzed the cytokine levels of two critical cytokines
known to affect antitumor immune responses: IL-10 is secreted by
T regulatory cells, macrophages, and MDSCs in the tumor envi-
ronment and dampens antitumor CD8+ T cell responses [23,24],
whereas IFN-γ promotes antitumor responses through stimulation
of the immune system [25]. Serum collected from the peritoneal
ascites of tumor-bearing control mice treated with untargeted toxin
contains robust IL-10 levels (Figure 3A) in conjunction with de-
pressed levels of IFN-γ (Figure 3B). However, on VLC depletion with
SR-A–targeted immunotoxin, IL-10 is diminished at the site of tumor
growth (Figure 3A), whereas the amount of IFN-γ in the peritoneum
of ID8 tumor-challenged mice increases on treatment with SR-A
immunotoxin (Figure 3B). These results demonstrate that the deple-
tion of SR-A+ cells in the peritoneum of tumor-bearing mice engen-
ders a profound change in the local cytokine environment. Because
our previous findings demonstrated that SR-A+ depletion slows tumor
growth, we tested whether the immune system contributes to the
SR-A immunotoxin effects.
Figure 2. VLC depletion reverses splenic immunosuppression. Mice were injected with 5 × 106 ID8-C3 cells and treated with either the
ribosomal toxin saporin conjugated to the 2F8 anti–SR-A monoclonal antibody (SRA-Zap) or with untargeted toxin (Zap). Mice were given
subsequent weekly injections of SRA-Zap or ZAP. After 7 weeks, mice were killed, and splenocytes were stimulated with media alone (neg),
αCD3 antibody (αCD3), or PMA and ionomycin (PMA) for 72 hours. (A) Culture supernatants were harvested, and IFN-γ was assessed by
ELISA. (B) Splenocytes were stained with CD11b and Gr-1 antibodies, and MDSC populations were assessed (representative FACS plot
shown). (C) Total numbers of peritoneal VLCs (CD11c+GFP−) (white bar) and percentages of splenic CD11b+Gr-1+ cells (black bar) from
Zap- and SRA-Zap–treatedmicewere compared. The population of cells in SRA-Zap–treatedmice in comparison to control mice is shown as
percent of control treatment. Statistical significance (*P < .05) was determined with the paired Student’s t test.
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Antitumor Effects of VLC Depletion Are Dependent on the
Immune System
The in vitro function of VLCs as MDSCs, along with the change in
cytokine milieu in ascites of VLC-depleted mice, suggested that acti-
vation of T cell activity through VLC depletion may be responsible
for the observed inhibition of tumor progression. We extended these
experiments to test whether SR-A immunotoxin affected the survival
of tumor-challenged RAG-knockout (RAG−/−) mice, which lack an
adaptive immune system. Wild type and RAG−/− were challenged with
ID8 tumors expressing GFP (ID8-C3) and were given one of two
treatments i.p. once weekly for 7 weeks: Zap immunotoxin (ZAP)
or SR-A–targeted ZAP toxin through conjugation with an anti-SRA
antibody (SRA) [14]. As previously demonstrated, the depletion of
SR-A+ cells from the peritoneum of ID8 tumor-challenged mice ex-
tends their survival (Figure 4) [14]. However, when RAG−/− mice were
injected with ID8 tumor cells and depleted of SR-A+ cells, the tumor
growth kinetics was similar to wild-type and RAG−/− mice given Zap
alone. Indeed, RAG−/− SR-A–depleted mice had a poorer survival than
wild type given the SR-A immunotoxin (P < .01). Because T cell ac-
tivity is proposed to contribute to tumor control in a variety of tumor
models, we tested more stringently the contribution of CD8+ T cells
to the efficacy of the SR-A immunotoxin. To test this hypothesis, we
performed the SR-A–mediated cellular depletion experiments in con-
junction with CD8-mediated depletion. Mice were challenged with
ID8-C3 tumors and were given one of four treatments i.p. once weekly
for 7 weeks: Zap immunotoxin (ZAP), CD8-depleting antibody (CD8),
SR-A–targeted ZAP toxin through conjugation with an anti-SRA anti-
body (SRA) [14], and CD8-depleting antibody along with anti–SR-A
antibody–conjugated ZAP toxin (CD8/SRA). After 7 weeks, all four
groups were killed, and tumor growth was assessed ex vivo. Consistent
with previous results [14], when SR-A+ cells are eliminated from the
tumor environment, there is a marked reduction in ascites volume,
ascites cellularity, ID8 tumor cells, and CD11c+ cells within the perito-
neum of tumor-challenged mice (Figure 5, A–D: compare Zap with
SRA). However, when a depleting CD8 antibody is administered along
with the SR-A immunotoxin, the SR-A depletion is markedly less effica-
cious (Figure 5, A–D: compare SRA with SRA/CD8). In particular,
the total numbers of ascites cells and ID8 tumor cells under conditions
of CD8 and SR-A depletion are significantly increased over SR-A deple-
tion alone (Figure 5, B andC). As a control, the number of CD11c+ cells
in the peritoneum of tumor-challenged mice is unaffected when CD8+
cells are depleted along with SR-A+ cells, indicating that the anti-CD8
antibody did not affect the efficacy of the SR-A immunotoxin treatments
(Figure 5D). The depletion of only CD8+ cells from the peritoneum
of mice had a minimal effect on any of the parameters assessed. These
data demonstrate the importance of CD8+ cells for the antitumor effects
of SR-A depletion. In conjunction with our data showing that SR-A
depletion changes the levels of peritoneal cytokines, this indicates that
SR-A depletion relieves immunosuppression allowing for the induction
of an antitumor response.
Therapeutic VLC Depletion from Established Peritoneal
Ascites Relieves T Cell Immunosuppression
Our previous experiments that demonstrate an immunologic effect
after VLC depletion used therapeutic intervention over the course of
the tumor challenge (Figures 2 and 3). To extend these studies to a
more therapeutically relevant intervention, we next tested whether
later-stage depletion of VLCs from mice bearing established tumors
affected the tumor-induced immunosuppression. To do so, we used
the MAFIA strain of mice [19]. The MAFIA mice contain a knock-in
GFP gene under the colony-stimulating factor-1 receptor (CSFR-1,
c-fms, CD115) promoter that renders monocyte-derived cells, preferen-
tially macrophages, GFP-positive [19]. In addition to a GFP knock-in,
Figure 4. SR-A depletion in RAG−/− background does not confer
a survival benefit. Wild-type or RAG−/− mice were challenged with
5 × 106 ID8-C3 cells and treated with weekly peritoneal injections
of either SRA-ZAP (WT-SRA or RAG-SRA) or with untargeted toxin
(WT or RAG). Mice were killed after gaining 75% of weight at time
of tumor injections. A Kaplan-Meier analysis was conducted on sur-
vival of each treatment group (WT vs WT-SRA, P < .01; RAG-SRA vs
WT-SRA, P < .05).
Figure 3. SR-A–mediated depletion alters the local cytokine environment. Mice were treated with tumors and SRA-Zap or Zap as in
Figure 2. After 7 weeks, ascites was harvested and spun, and ascites serum was collected. Concentrations of IL-10 (A) or IFN-γ (B) were
assessed by ELISA. Statistical significance (**P < .01; ***P < .005) was determined with the paired Student’s t test.
Translational Oncology Vol. 2, No. 4, 2009 Ovarian Cancer Induced Immunosuppression Bak et al. 295
MAFIA mice contain a cell surface receptor that, when dimerized
with the small molecule AP20187, induces cellular apoptosis [19,20].
We have previously shown that, consistent with previous reports of
CD115+ as a marker MDSCs [26], the VLC population in ID8 ovarian
ascites expresses GFP in theMAFIAmouse [17]. To determine whether
we could deplete VLCs from mice bearing established tumors, we
injected AP20187 into ID8-challenged MAFIA mice. Delivery of
AP20187 depleted the CD115+CD11c+ immunosuppressive cell popu-
lation when injected i.p. into 6-week tumor-bearing mice (Figure 6A).
To determine whether peritoneal depletion of VLCs from mice bearing
ID8 ascites affected late-stage tumor-induced immunosuppression,
6 weeks after ID8 tumor initiation, we injected AP20187 or vehicle
into the peritoneum of these mice three times over the course of 5 days.
The day after the last AP20187 injection, the mice were killed, spleno-
cytes were stimulated with PMA and ionomycin, and CD8+ T cell
activation was assessed by intracellular cytokine staining for IFN-γ pro-
duction. In non–tumor-bearing naive mice, a significant amount of
CD8+ T cells respond to PMA with the production of IFN-γ (Fig-
ure 6B). However, mice challenged with ID8 tumors and treated with
vehicle had 75% less CD8+IFN-γ+ cells when stimulated with PMA
compared with naive mice. After three injections of AP20187, in vitro
T cell responses from tumor-bearingmice were restored to ∼70% of that
of naive mice (Figure 6C). To determine whether this short-term deple-
tion of immunosuppressive cells affected the ability to raise a peptide-
specific response, we performed a variation on the previous experiment
in which we immunized mice with SIINFEKL peptide, the H2-Kb–
restricted epitope of chicken albumin (Figure 7A). Briefly, MAFIAmice
were injected with ID8 tumors, and 6 weeks later, mice were given
AP20187 injections every other day for 5 days. On day 5, mice were
retro-orbitally injected with 2 μg of SIINFEKL plus adjuvant. After
72 hours, mice were killed and splenic T cells were stimulated either
with PMA and ionomycin or with 1 μg/ml SIINFEKL peptide. In sup-
port of the previous results (Figure 6C ), short-term administration of
AP20187 partially restored the ability of CD8+ T cells to produce
IFN-γ in response to PMA when compared to those treated with
vehicle (Figure 7B). Interestingly, when restimulated in vitro with pep-
tide, the CD8+IFN-γ+ cell population of AP20187-treated mice is
∼75% of immunized naive mice, in comparison to 50% for vehicle-
treated mice (Figure 7C ). These results provide the first demonstra-
tion that short-term depletion of VLCs improves both polyclonal and
peptide-specific T cell responses in secondary lymphoid organs of
ovarian tumor–bearing mice.
Discussion
The critical role that the immune system has in modulating tumor
growth is now recognized [1]. The tumor, and its resultant micro-
environment, recruits a local population of dysregulated immune cells
that aid in tumor growth [27]. Many murine tumor models, including
lung, breast, and colon, recruit an influx of immunosuppressive leuko-
cytes [28–30]. Specifically, both human and murine ovarian tumor
growth induces an influx of CD11b+CD11c+ leukocytes to the perito-
neal tumor environment that is critical to tumor progression [15,31].
These VLCs are critical to tumor growth because their selective re-
moval slows tumor growth [14,32]. However, how VLC depletion in-
hibits tumor progression is not well understood. A recent clue was the
elucidation that VLCs can function asMDSCs: VLCs express ARG1 and
are immunosuppressive in vitro [14,33]. In numerous tumor models,
the presence of MDSCs correlates with a globally depressed immune
Figure 5. Depletion of SR-A+ cells requires CD8+ T cells for effect. Mice were challenged with 5 × 106 ID8-C3 cells and treated with weekly
peritoneal injections of either SRA-ZAP, with untargeted toxin (Zap), anti-CD8 antibody (CD8), or with SRA-ZAP and anti-CD8 antibody (CD8/
SRA). Four variables of tumor progression were assessed for each treatment group. Peritoneal exudates were measured for the ascites
volume (A), total numbers of cells within the ascites (after RBC lysis; B), the quantity of GFP+ ID8-C3 tumor cells (C), and the quantity of
CD11c+ VLCs (D). CD11c+ VLCs and GFP+ tumor cells were quantified by FACS analysis. Statistical significance (SRA vs ZAP, **P < .01,
***P < .005; SRA vs CD8/SRA, #P < .05, ##P < .01) was determined with the paired Student’s t test.
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response [21,34]. Therefore, we hypothesized that ID8 ovarian tumor
growth may induce immunosuppression both locally and distally to
tumor growth and that depletion of the immunosuppressive VLC popu-
lation may alleviate the immunosuppression.
Here we demonstrate that the growth of ID8 tumors impacts the
immune status of lymphoid tissues distal to tumor growth. T cells re-
covered from ID8 tumor-bearing mice secrete less IFN-γ compared
with naive controls (Figure 1A). Furthermore, the CD11b+ compart-
ment within spleens of tumor-bearing mice recapitulates this pheno-
type, as coculture of CD11b+ cells from tumor-bearing mice causes a
diminution of IFN-γ release from naive T cells when compared with
CD11b+ splenocytes isolated from naive controls (Figure 1B). These
data are supported by findings that splenic MDSCs from tumor-
bearing hosts are consistently more suppressive than those from naive
controls [18]. Relevant to human disease, our data support clinical
findings because peripheral blood mononuclear cell of late-stage
ovarian patients are unable to respond to stimuli as effectively as healthy
controls [35,36]. Moreover, dysregulated signaling in the CD8 T cell
compartment of ovarian cancer patients is well established [37]. Cou-
pled with our previous findings that VLC depletion slows tumor growth
[14], these data led us to define the effect of VLC depletion on T cell
responses in ID8 tumor-bearing mice.
In tumor-challenged mice depleted of VLCs, their T cells produce
more IFN-γ in response to T-cell receptor stimulation and mitogen
activation than T cells from the control mice (Figure 2). One under-
lying reason for the increased T cell activation after VLC depletion
may reside in the resultant cytokine environment. Depletion of VLCs
led to the reduction in levels of IL-10 and to an increase in the con-
centration of IFN-γ within the tumor microenvironment (Figure 3).
This switch from a tolerogenic cytokine profile to one that is associated
with proinflammatory antitumor responses led us to ask whether the
inhibition in tumor progression mediated by VLC depletion was de-
pendent on T cell–dependent responses. RAG−/− mice depleted of
VLCs did not exhibit the survival benefit of wild-type mice depleted
of VLCs (Figure 4). Extending these results to specifically test which
cellular subsets are necessary for SR-A immunotoxin effects, mice were
depleted of VLCs using the SR-A immunotoxin with and without CD8
depletion. Mice depleted of CD8+ T cells along with VLCs had both
higher levels of total peritoneal cells within the ascites and of ID8 tumor
cells 7 weeks after tumor challenge (Figure 5, B and C). In addition,
mice depleted of VLCs and CD8+ T cells did not exhibit the survival
benefit of mice depleted of VLCs alone (Figure 5). These data are con-
sistent with findings in other tumor models wherein activation of CD8+
T cell responses can limit tumor progression and lead to reduced tumor
burden [34,38–40]. Interestingly, despite the substantial reduction in
cellularity within the peritoneum of VLC-depleted mice relative
to those that also received CD8 depletion, VLC- and VLC/CD8–
depleted mice contained similar levels of ascites volume (Figure 5A).
Figure 6. Short-term VLC depletion relieves immunosuppression. (A) MAFIA mice were challenged with 5 × 106 ID8-C3. After 6 weeks,
mice were injected with AP20187 (AP20187) or injection solution (Control) for three straight days. Mice were killed, and post-RBC lysis of
ascites was stained with CD11c antibody and VLC population (GFP+CD11c+) population was assessed by FACS. (B) Splenocytes from
naive MAFIA mice were harvested and left unstimulated (white bar) or stimulated with PMA/ionomycin for 5 hours (black bar). Cells were
stained for CD8 and intracellular IFN-γ. CD8+IFN-γ+ cells were determined by FACS. (C) MAFIA mice were challenged with 5 × 106 ID8-C3.
After 6 weeks, mice were injected with AP20187 (AP20187) or injection solution (Vehicle) every other day for 5 days. At 24 hours after the
last injection, mice were killed, and splenocytes were harvested. Splenocytes from AP20187-treated (AP20187) and injection solution–
treated (Vehicle) were stimulated with PMA/ionomycin. Cells were stained for CD8 and intracellular IFN-γ. CD8+IFN-γ+ cells were de-
termined by FACS and expressed as a percentage of CD8+IFN-γ+ cells from non–tumor-bearing naive mice, as determined in panel B.
Statistical significance (*P < .05) was determined with the paired Student’s t test.
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Because VLCs promote angiogenesis [2,15], the lack of substantial ascites
in both instances could be due to their removal under both conditions.
To confirm the results obtained with the SR-A immunotoxin, as
well as to extend our studies to test the more therapeutically relevant
trial of short-term VLC depletion in mice bearing established tumors,
we made use of the MAFIA strain of mice. These mice express a GFP
transgene under the CD115 promoter, which previous data have shown
corresponds with, and identifies, the CD11b+CD11c+ VLC population
within ID8 ascites (Figure 6A and [17]). CD115+ cells in MAFIA
mice also harbor a cell surface receptor which, on dimerization with
the small molecule AP20187, leads to cellular apoptosis [19,20]. Intra-
peritoneal AP20187 injection effectively reduced the number of VLCs
within late-stage peritoneal ascites (Figure 6). Importantly, three daily
treatments within the sixth week of ID8-C3 tumor-challenged MAFIA
mice relieved tumor-induced immunosuppression as assessed by ex vivo
T cell stimulation (Figure 6C). To extend these results, we tested whether
VLC depletion could improve a peptide-specific T cell response against a
model tumor antigen. Depletion of VLCs for 5 days followed by immu-
nization against the SIINFEKL peptide, improved the in vitro recall
response in tumor-bearing mice (Figure 7C). These data demonstrate
that depletion of immunosuppressive cells at the site of tumor growth
relieves tumor-induced immune suppression and restores normal func-
tion of the immune system. Because these effects are seen inmice bearing
well-established tumors, it is tempting to speculate on the therapeutic
benefit of a combination of VLC depletion coupled with vaccination
against known tumor-associated antigens.
These data reveal another facet in which the ID8 tumor model re-
capitulates the human disease in mice, making it a tractable model for
studying immune dysfunction in ovarian cancer. This study outlines
multiple novel interactions between ID8 tumor growth and the im-
mune system, including the induction of distal immunosuppression in
lymphoid tissues, the reversal of immune suppression through perito-
neal leukocyte depletion, and the dependence of antitumor leukocyte
depletion on CD8+ T cells. The ability to reverse the immuno-
suppression through two different modes of leukocyte depletion pro-
vides a powerful tool for further studies into tumor/immune system
interactions. Because the molecular mechanisms behind tumor-induced
T cell tolerance are not fully understood, models such as this will prove
useful in answering these questions. As cancer therapies attempting to
initiate an immune response against cancer have garnered mixed results
[27], studies such as these add to the growing body of evidence that com-
plementary depletion of immunosuppressive cells is a viable avenue for
novel cancer treatments.
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Figure 7. VLC depletion potentiates the induction of a peptide specific immune response. (A) MAFIA mice were challenged with 5 × 106
ID8-C3. After 6 weeks, mice were injected with AP20187 (AP20187) or injection solution (Vehicle) for every other day for 5 days. On the
fifth day, mice were injected with 2 μg of SIINFEKL peptide/10 μg of lipopolysaccharide/100 μg of agonistic αCD40 antibody. As a control,
naiveMAFIAmicewere also immunized at this point. (B) After 72 hours, AP20187-treated (AP20187), injection solution–treated (Vehicle), and
immunized naive mice were killed and spleens were stimulated with PMA/ionomycin. After 5 hours, cells were harvested and stained for
CD8 and intracellular IFN-γ. Cells were analyzed by FACS, and the percentage CD8+IFN-γ+ cells compared with naive immunized mice
were determined. (C) Mice were treated as in panel B, except stimulated with 1 μg/ml SIINFEKL peptide and analyzed as a percentage of the
CD8+IFN-γ+ cells produced from naive mice. Statistical significance (*P < .05; **P < .01) was determined with the paired Student’s t test.
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